Innate Pharma S.A. — Company profile
Healthcare · Biotechnology · France
Last price 1.5 USD (Oct 30, 2026, 9:37 AM EDT) · Market cap 134.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Details
| Name | Innate Pharma S.A. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 120 |
| Founded | 1999 |
| Ipo Date | 2019-10-17 |
| Ceo | Jonathan Dickinson |
| Country | France |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| Ipo Price | 5.50 |
| Isin | US45781K2042 |
| Cusip | 45781K204 |
| Cik | 1598599 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Jonathan E. Dickinson B.Sc., M.B.A. | Chief Executive Officer and Director |
| Yannis Morel Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. François Romagné Ph.D. | Founder |
| Dr. Marc Bonneville Ph.D. | Founder |
| Jean Jacques Fournié Ph.D. | Founder |
| Alessandro Moretta M.D., Ph.D. | Founder |
| Frederic Lombard M.B.A. | Senior Vice President and Chief Financial Officer |
| Stephanie Cornen | Vice President of Investor Relations, Communication and Commercial Strategy |
| Odile Belzunce | Vice President, Chief of Compliance and Operations Officer and Interim Head of Human Resources |
| Claire de Saint Blanquat | Vice President of Legal and Corporate Affairs and Secretary of the Supervisory Board |
Contact
| Address | 117, Avenue de Luminy, BP 30191, Marseille, 13009, France |
| Phone | 33 4 30 30 30 30 |
| Website | https://www.innate-pharma.com |